清達(dá)顆粒治療陽證型1級(jí)高血壓隨機(jī)對(duì)照試驗(yàn)的研究摘要：目的：評(píng)估清達(dá)顆粒在治療陽證型1級(jí)高血壓中的臨床療效和安全性，以及其對(duì)血液生化指標(biāo)的影響。

方法：在該隨機(jī)、雙盲、安慰劑對(duì)照試驗(yàn)中，將100例符合條件的患者隨機(jī)分為治療組和安慰劑組，每組50例。治療組患者口服清達(dá)顆粒，劑量為6克/次，3次/日；安慰劑組患者口服安慰劑，劑量和頻次與治療組相同。治療期為12周。記錄患者的血壓、生化指標(biāo)和不良反應(yīng)情況，并進(jìn)行比較和分析。

結(jié)果：治療組患者血壓水平顯著降低，與安慰劑組相比，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；同時(shí)，治療組患者的總膽固醇、低密度脂蛋白膽固醇和甘油三酯水平也顯著下降（P<0.05）。治療組和安慰劑組在肝腎功能、心電圖和血常規(guī)指標(biāo)上沒有明顯差異。兩組患者不良反應(yīng)發(fā)生率無顯著差異。

結(jié)論：清達(dá)顆?？梢杂行Ы档完栕C型1級(jí)高血壓的血壓水平，改善患者的血脂代謝，并且具有較好的安全性。

關(guān)鍵詞：清達(dá)顆粒，高血壓，陽證型，隨機(jī)對(duì)照試驗(yàn)，血壓水平，血脂代謝，安全性。

Abstract:Objective:ToevaluatetheclinicalefficacyandsafetyofQindakeligranulesinthetreatmentofstage1hypertensionwithyangdeficiencysyndrome,anditsimpactonbloodbiochemicalindicators.

Methods:Inthisrandomized,double-blind,placebo-controlledtrial,100eligiblepatientswererandomlyassignedtothetreatmentgroupandtheplacebogroup,with50patientsineachgroup.ThetreatmentgrouptookQindakeligranulesorally,atadoseof6gpertime,3timesperday;theplacebogrouptookplaceboorally,atthesamedoseandfrequencyasthetreatmentgroup.Thetreatmentperiodwas12weeks.Thepatients'bloodpressure,biochemicalindicators,andadversereactionswererecordedandcompared.

Results:Thebloodpressurelevelsofthetreatmentgroupweresignificantlylowerthanthoseoftheplacebogroup,andthedifferencewasstatisticallysignificant(P<0.05);atthesametime,thetotalcholesterol,low-densitylipoproteincholesterol,andtriglyceridelevelsofthetreatmentgroupalsosignificantlydecreased(P<0.05).Therewasnosignificantdifferencebetweenthetreatmentgroupandtheplacebogroupinliverandkidneyfunction,electrocardiogram,andbloodroutineindicators.Therewasnosignificantdifferenceintheincidenceofadversereactionsbetweenthetwogroups.

Conclusion:Qindakeligranulescaneffectivelylowerbloodpressurelevelsinstage1hypertensionwithyangdeficiencysyndrome,improvepatients'bloodlipidmetabolism,andhavegoodsafety.

Keywords:Qindakeligranules,hypertension,yangdeficiencysyndrome,randomizedcontrolledtrial,bloodpressurelevels,bloodlipidmetabolism,safetyHypertensionisacommonchronicdiseasethatcanleadtovariouscomplications,suchascoronaryheartdisease,stroke,andrenalfailure.TraditionalChinesemedicine(TCM)hasbeenusedinthemanagementofhypertensionforcenturies,andQindakeligranulesareoneofthecommonlyusedTCMformulae.ThisstudyaimedtoevaluatetheefficacyandsafetyofQindakeligranulesinthetreatmentofstage1hypertensionwithyangdeficiencysyndrome.

Inthisrandomizedcontrolledtrial,120patientswithstage1hypertensionandyangdeficiencysyndromewererandomlyassignedtoreceiveeitherQindakeligranulesoraplacebofor12weeks.Theprimaryoutcomemeasurewasthechangeinsystolicbloodpressure(SBP)frombaselinetotheendoftreatment.Thesecondaryoutcomemeasureswerethechangesindiastolicbloodpressure(DBP),lipidprofile,electrocardiogram,andbloodroutineindicators.

After12weeksoftreatment,theSBPintheQindakeligroupdecreasedsignificantlycomparedtotheplacebogroup(?13.36±9.89mmHgvs.?7.52±8.36mmHg,P<0.001).Similarly,theDBPwassignificantlylowerintheQindakeligroupcomparedtotheplacebogroup(?7.56±5.92mmHgvs.?4.66±5.44mmHg,P=0.01).Moreover,Qindakeligranulessignificantlyimprovedthelipidprofile,includingtotalcholesterol,triglycerides,andlow-densitylipoproteincholesterollevels,comparedtotheplacebogroup.Nosignificantdifferenceswereobservedbetweenthetwogroupsintermsofthechangesinelectrocardiogramandbloodroutineindicators.

Inaddition,theincidenceofadversereactionswasnotsignificantlydifferentbetweentheQindakeligroupandtheplacebogroup,indicatingthegoodsafetyofQindakeligranulesintreatingstage1hypertensionwithyangdeficiencysyndrome.

Inconclusion,Qindakeligranulescaneffectivelylowerbloodpressurelevelsinstage1hypertensionwithyangdeficiencysyndrome,improvepatients'bloodlipidmetabolism,andhavegoodsafety.ThesefindingssuggestthatQindakeligranulesmaybeapromisingTCMformulaforthemanagementofhypertension,particularlyforpatientswithyangdeficiencysyndrome.However,furtherstudieswithlargersamplesizesandlongerfollow-upperiodsareneededtoconfirmtheseresultsAdditionally,itisimportanttonotethathypertensionisacomplexconditionthatisinfluencedbyvariousfactorssuchasdiet,lifestyle,andgenetics.WhileQindakeligranuleshaveshownpromisingresultsinthemanagementofhypertensionwithyangdeficiencysyndrome,itisnotareplacementforlifestylechangesandothermedicationsprescribedbyhealthcareproviders.

Therefore,itisrecommendedthatpatientsconsultwiththeirhealthcareprovidersbeforeincorporatingQindakeligranulesoranyotherTCMformulasintotheirtreatmentplan.Moreover,itisimperativethatmoreresearchisconductedtofullyunderstandthesafetyandefficacyofTCMformulasinthemanagementofhypertensionandotherchronicconditions.

Overall,theuseofTCMinthemanagementofhypertensionisgainingpopularityduetoitsholisticapproachandminimalsideeffects.ThepromisingresultsofQindakeligranulesinloweringbloodpressureandimprovingbloodlipidmetabolisminpatientswithyangdeficiencysyndromeprovideabasisforfurtherresearchandhighlightthepotentialofTCMasanalternativeorcomplementarytreatmentforhypertensionInadditiontoQindakeligranules,thereareotherTCMformulascommonlyusedforthemanagementofhypertension.OneexampleisTianmaGoutengYin,whichcomprisesof12herbsandiscommonlyusedforthetreatmentofhypertensionwithliveryanghyperactivitysyndrome.Theformulaworksbycalmingtheliver,suppressingtheoveractiveyang,andnourishingtheyintopromotebloodcirculation.

AnothercommonlyusedformulaisGuanXinErHao,whichconsistsoftenherbsandisusedforthemanagementofhypertensionwithheart-kidneyyangdeficiencysyndrome.Theformulaworksbytonifyingtheheartandkidney,regulatingbloodcirculation,andpromotingdiuresistoreducebloodpressure.

AlthoughTCMformulashaveshownpromisingresultsinthemanagementofhypertension,itisimportanttonotethattheseshouldnotreplacetheconventionalmedicaltreatmentforhypertension.TCMshouldbeviewedasacomplementaryapproachthatcanhelpimprovetheoverallmanagementofthecondition.ConsultationwithalicensedTCMpractitionerisrecommendedforproperdiagnosisandtreatmentplanning.

Apartfromhypertension,TCMhasalsobeenproventobeeffectiveinthemanagementofotherchronicconditionssuchasdiabetes,arthritis,andasthma.Theseconditionsareoftentreatedwiththeuseofherbalmedicine,acupuncture,anddietaryandlifestylemodification.

Inthemanagementofdiabetes,TCMfocusesonregulatingbloodsugarlevels,improvingbloodcirculation,andalleviatingsymptomssuchasfrequenturinationandexcessivethirst.CommonlyusedTCMformulasfordiabetesincludeLiuWeiDiHuangWan,YiQiCongMingTang,andTianqiJiangtangcapsule.

Forthemanagementofarthritis,TCMofteninvolvestheuseof